BIOXYTRAN, INC 1Q 2026: Net loss $(2.07M), EPS $(0.02) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.BIOXYTRAN, INC reported a net loss of $(2.07M) and EPS of $(0.02) for Q1 2026, compared to a net loss of $(1.35M) in Q1 2025. The company remains pre-revenue while advancing its pipeline, including promising therapeutics and clinical milestones. Management is focusing on R&D and plans to raise capital to support development, with Phase 3 trials expected to start in Q3 2026, contingent on funding.
BIOXYTRAN, INC reported a first-quarter 2026 net loss of $(2.07M) and diluted EPS of $(0.02), compared with a net loss of $(1.35M) and EPS of $(0.02) in the year-ago quarter. The company remains pre-revenue as it continues clinical and development work across its pipeline.
Financial Highlights
- Revenue: No revenue reported for 1Q 2026 (company remains pre-revenue / clinical-stage).
- Net income: Net loss of $(2.07M) for 1Q 2026 vs. net loss of $(1.35M) in 1Q 2025 (worse YoY).
- Diluted EPS: $(0.02) for 1Q 2026, flat vs. $(0.02) in 1Q 2025.
Business Highlights
- Pipeline progress: Advanced multiple therapeutics, including BXT-25 AOC which showed encouraging animal safety data; ProLectin programs are moving toward Phase 3 planning.
- Clinical milestones: A Phase 1b/2a oral COVID study showed faster viral clearance at the highest dose; INDs for trials were approved by the FDA and CDSCO.
- Operational focus: Management is prioritizing R&D and regulatory activities with planned Phase 3 starts in Q3 2026, conditional on securing additional funding.
- Funding-dependent roadmap: The company plans to raise capital to sustain development; the timing of financing will directly affect trial starts and timelines.
Original SEC Filing: BIOXYTRAN, INC [ BIXT ] - 10-Q - May. 15, 2026